Biognosys Announces Facility Expansion to Support Large-Scale Proteomics | Biognosys
Contact us Helpdesk

Biognosys Announces Facility Expansion to Support Large-Scale Proteomics

16 December 2020 – SCHLIEREN (Zürich – Switzerland). Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces an expansion of its facilities with an additional office and laboratory 900 square meters (9687 sqft) site in the Bio-Technopark at Wagistrasse 18, Schlieren, Zurich.

Through this extension, Biognosys will operate one of the largest high-end Mass Spectrometry laboratories worldwide and will be able to offer Large-Scale Proteomics contract research services to global pharma and biotech customers.

Uniquely equipped with automation and parallelization, the lab will provide industry-leading sample throughput and project turnaround times, enabling analysis of thousands of proteins in thousands of samples for multiple parallel projects.

The lab will conform with the GxP quality guidelines and regulations, applicable to the processing of human samples for clinical trials in the regulated market.

In addition to this facility extension for contract research services, Biognosys continues to develop its portfolio of software and reagent products for proteomics data analysis, powered by machine learning and artificial intelligence algorithms.

 

 

“With this expansion we are well prepared to drive the transition towards proteomics as a source of functional data next to genomics at a large scale.”

 

Dr. Oliver Rinner,
CEO of Biognosys

 

Thanks to its state-of-the-art facility, proprietary technologies and versatile portfolio of products and services, Biognosys is uniquely positioned to offer next-generation proteomics at the quality, scale, and speed required to transform R&D, clinical trials, and in the future clinical decision making.

 

About Biognosys

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by developing the most advanced proteomics tools and making them available for pharmaceutical and biotech research and development. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with a deep view of protein expression and regulation in cells, tissues, or body fluids. Biognosys’ technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at www.biognosys.com

 

Media Contact:

Oliver Rinner, PhD
Chief Executive Officer
Phone +41 (0) 44 738 20 45
Mobile +41 (0) 78 664 47 11
oliver.rinner@biognosys.com

 

 

Download PFD version (English)

Back to News overview